Key result
HeartLogic sensors detect a ~4.7 br/min respiratory rate increase in COVID-19 versus heart failure.
Why the study?
Implantable device-based sensors predict HF hospitalizations, but how these parameters change prior to COVID-19 and compare with decompensated HF or pneumonia was unknown.
Do multiparameter implantable diagnostic sensor measurements differ prior to presentation with COVID-19 compared with decompensated heart failure or pneumonia in patients with heart failure?
Observational (n=110)
Yes
Do multiparameter implantable diagnostic sensor measurements differ prior to presentation with COVID-19 compared with decompensated heart failure or pneumonia in patients with heart failure?
Multiparameter implantable defibrillator sensors can help distinguish early COVID-19 infection from decompensated heart failure by identifying a rapid, marked rise in respiratory rate and pulse generator temperature in the absence of S3 heart sound changes or thoracic impedance drops.
Answers are grounded in this paper and cite their sources.
May aid differentiation of COVID-19 from HF decompensation via sensor trends; leaves open prospective validation before clinical use.
Aims Implantable device-based sensor measurements including heart sounds, markers of ventilation, and thoracic impedance have been shown to predict heart failure (HF) hospitalizations. We sought to assess how these parameters changed prior to COVID-19 (Cov-19) and how these compared with those presenting with decompensated HF or pneumonia. Methods and results This retrospective analysis explores patterns of changes in daily measurements by implantable sensors in 10 patients with Cov-19 and compares these findings with those observed prior to HF (n = 88) and pneumonia (n = 12) hospitalizations from the MultiSENSE, PREEMPT-HF, and MANAGE-HF trials. The earliest sensor changes prior to Cov-19 were observed in respiratory rate (6 days) and temperature (5 days). There was a three-fold to four-fold greater increase in respiratory rate, rapid shallow breathing index, and night heart rate compared with those presenting with HF or pneumonia. Furthermore, activity levels fell more in those presenting with Cov-19, a change that was often sustained for some time. In contrast, there were no significant changes in 1st or 3rd heart sound (S1 and S3) amplitude in those presenting with Cov-19 or pneumonia compared with the known changes that occur in HF decompensation. Conclusions Multi-sensor device diagnostics may provide early detection of Cov-19, distinguishable from worsening HF by an extreme and fast rise in respiratory rate along with no changes in S3.
No takes yet. Share an insight, caveat, or question.
Gardner et al. (2021) conducted an observational in Heart failure with implantable defibrillator presenting with COVID-19, decompensated heart failure, or pneumonia (n=110). SARS-CoV-2 infection (COVID-19) evaluated via implantable multiparameter HeartLogic device sensors vs. Decompensated heart failure (n=88) and pneumonia (n=12) events was evaluated on Pre-event change in device-measured respiratory rate from baseline (br/min) (p=0.003). Implantable HeartLogic sensors in COVID-19 patients detected a 4.7 br/min rise in respiratory rate and no change in S3 amplitude prior to presentation.
Synapse has enriched 10 related papers. Consider them for comparative context: